-
Business Standard had reported that several senior executives have been asked to resign amid Revlimid-linked margin strain, a claim that has been denied by the company.
-
The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially impacting companies like Dr Reddy's Laboratories, Zydus, and Cipla.
-
Dr Reddy's Q2 results: Revenue rises 17% to Rs 8,106 crore
-
Dr Reddy’s will have to invest significantly to improve growth rates of the acquired brands in nicotine replacement therapy
-
A joint press release from the companies said the partnership will bring together the well-known global range of nutritional health solutions as well as vitamins, minerals, herbals and supplements of Nestle Health Science (NHSc) with the strong and established commercial strengths of Dr Reddy's in India.
-
Pharma sector to be in focus this week in F&O segment with strong long build up witnessed in stocks like Zydus Life, Lupin, Lauruslabs, Divislab, and Dr. Reddy's.
-
According to the terms of the definitive agreement, Torrent Pharma will take over the manufacturing, marketing and distribution of these brands in India.
-
Kotak Institutional Equities expects North America business (including Canada) to increase by $11 million q-o-q to $246 million, and forecasts 25% y-o-y growth in India from recovery in acute segment and contribution from Sputnik vaccine.
-
The company has committed to reducing its Scope 1 and 2 greenhouse gas emissions by 55 percent by 2030, keeping 2017-18 as the base year. It is the first Indian and the third Asian pharmaceutical company to join the Science-Based Targets initiative (SBTi) for minimising environmental harm.
-
"Promius Pharma, LLC, has sold its rights of Cloderm (clocortolone pivalate) cream, 0.1 per cent and its authorised generic to EPI Health, LLC, an affiliate of EPI Group, LLC," DRL said in a statement
-
Dr Reddy's acquired Cloderm Cream from Valeant Pharmaceuticals in April 2011 for an undisclosed amount
-
Trends on SGX Nifty indicate a positive opening for the broader index in India, a rise of 12 points or 0.11 percent. Nifty futures were trading around 11,035-level on the Singaporean Exchange.
-
Having launched operations in France, Italy, Romania and Spain, the drug maker should be working on generating higher revenues from these countries, and to increase its market presence in Europe in the near future.
-
Atorvastatin is a drug that blocks the production of cholesterol and reduces its level in the blood.
-
In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.
-
The drug maker, besieged by pricing pressures and regulatory problems at its facilities, is looking to sell its oral penicillin manufacturing site in Bristol, US and brands such as Augmentin, Amoxil and other penicillin abbreviated new drug applications (ANDAs).
-
The lawsuit alleged that, Dr Reddy’s, between June 17, 2015 and August 10, 2017, made false or misleading statements and failed to disclose the lack of an effective corporate quality system.
-
Axis Direct recommended hold rating on Dr Reddy's Laboratories with a target price of Rs 2450 in its research report dated May 18, 2017.
-
Though the protection of surnames as trademark is difficult, yet we are surrounded by surnames as registered trademarks.
-
Ventura Securities has recommended hold rating on Dr Reddy Laboratories (DRL), in its February 21, 2013 research report. The research firm, expects company's performance in FY14 to remain muted and restricted to single digit growth.
-
Kronos implements its workforce management solution at Dr. Reddy's Laboratories.
-
Speaking to CNBC-TV18 on the quarter gone by, GV Prasad, Vice Chairman & CEO, Dr Reddy Laboratories said operating expenses have increased due to one-time litigation costs.
